Theranos today announced that a key role has been filled on the company’s executive team, with the arrival of Cass Grandone as Senior Vice President of Product Development.
Theranos reaches settlement with Partner Fund Management. Tender offer recapitalizing major shareholders scheduled to close May 15.
Company to reimburse more than those whose tests were voided and corrected; Resolution ends all existing and potential claims against Theranos in the state.
CMS withdraws revocation of CLIA certificates and reduces civil monetary penalty; Theranos withdraws appeal, completing exit from the clinical lab business.
Theranos, Inc. announced that engineering and biomedical device design experts have joined the company’s newly created Technology Advisory Board (TAB).
Riley Bechtel Retires from Board; Company to Retire Board of Counselors Structure in Consolidation of Advisory Framework